Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240013/S031

Sphere-9 Catheter and Affera Ablation System

Medtronic, Inc. · Decision date Oct 2, 2026

MEDTECHLEDGER EXPLANATIONP240013/S031

What did the FDA approve?

The FDA record for P240013/S031 lists a real-time process supplement for labeling changes to the Sphere-9 Catheter and Affera Ablation System, a percutaneous cardiac ablation catheter for treating atrial fibrillation with irreversible electroporation. The listed statement describes the action only as "for changes to the instructions for use (IFU)," and the supplement reason names modifications to indications, instructions, shelf life, or tradename.

The identifier links this supplement to PMA P240013, but the decision applies to a supplement rather than a new approval of the whole system. The record does not specify which IFU section changed, whether indications were modified, or what the changed text says. Nothing here independently establishes safety, clinical effectiveness, or a new indication; the reported purpose is labeling, not evidence.

FDA approval order statement

for changes to the instructions for use (IFU)
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Oct 2, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240013/S031
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
APPR
Decision date
Oct 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P240013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240013 · Original PMA

    Sphere-9 Catheter and Affera Ablation System

  2. P240013/S031 received

    Application receipt date recorded by FDA.

  3. P240013/S031 · FDA decision

    Real-Time Process

  4. P240013/S028 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  5. P240013/S032 · Related supplement

    Affera Sphere-9 Mapping and Ablation Catheter

Timeline entries are records held by MedtechLedger for P240013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240013

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalOct 24, 2024FDA
Medtronic, Inc.PMA supplementOct 6, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records